Hiberix
Details for Hiberix vaccine and its components.
Sponsor:
GlaxoSmithKline Australia
Administration route:
Intramuscular injection
Vaccine group:
Monovalent vaccines
Registered for use in infants and children aged 2 months to 5 years.
Monovalent Haemophilus influenzae type b (Hib) vaccine.
Lyophilised pellet in a monodose vial with separate diluent.
Each 0.5 mL reconstituted dose contains:
- 10 µg Hib capsular polysaccharide (polyribosyl-ribitol-phosphate) conjugated to approximately 25 µg tetanus toxoid (PRP-T)
For full details, refer to the product information and consumer medicine information sheets for Hiberixv vaccine available on the TGA website.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- PRP
- polyribosylribitol phosphate
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/hiberix.